Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02115, USA.
Department of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, 82152 Planegg, Germany.
Cell Chem Biol. 2022 Aug 18;29(8):1273-1287.e8. doi: 10.1016/j.chembiol.2022.06.007. Epub 2022 Jul 14.
Reactivation of fetal hemoglobin expression by the downregulation of BCL11A is a promising treatment for β-hemoglobinopathies. A detailed understanding of BCL11A-mediated repression of γ-globin gene (HBG1/2) transcription is lacking, as studies to date used perturbations by shRNA or CRISPR-Cas9 gene editing. We leveraged the dTAG PROTAC degradation platform to acutely deplete BCL11A protein in erythroid cells and examined consequences by nascent transcriptomics, proteomics, chromatin accessibility, and histone profiling. Among 31 genes repressed by BCL11A, HBG1/2 and HBZ show the most abundant and progressive changes in transcription and chromatin accessibility upon BCL11A loss. Transcriptional changes at HBG1/2 were detected in <2 h. Robust HBG1/2 reactivation upon acute BCL11A depletion occurred without the loss of promoter 5-methylcytosine (5mC). Using targeted protein degradation, we establish a hierarchy of gene reactivation at BCL11A targets, in which nascent transcription is followed by increased chromatin accessibility, and both are uncoupled from promoter DNA methylation at the HBG1/2 loci.
通过下调 BCL11A 来重新激活胎儿血红蛋白的表达是治疗β-血红蛋白病的一种很有前途的方法。由于迄今为止的研究使用了 shRNA 或 CRISPR-Cas9 基因编辑的干扰,因此缺乏对 BCL11A 介导的 γ-珠蛋白基因 (HBG1/2) 转录抑制的详细了解。我们利用 dTAG PROTAC 降解平台在红细胞中急性耗尽 BCL11A 蛋白,并通过新生转录组学、蛋白质组学、染色质可及性和组蛋白分析来检查其后果。在 31 个受 BCL11A 抑制的基因中,HBG1/2 和 HBZ 在 BCL11A 缺失时表现出转录和染色质可及性最丰富和最具渐进性的变化。在 BCL11A 缺失后,HBG1/2 的转录变化在<2 小时内即可检测到。急性 BCL11A 耗竭后,HBG1/2 发生强烈的重新激活,而启动子 5-甲基胞嘧啶 (5mC) 并未丢失。通过靶向蛋白降解,我们确定了 BCL11A 靶基因的基因重新激活层次,其中新生转录紧随染色质可及性增加,而这两者都与 HBG1/2 基因座的启动子 DNA 甲基化无关。